Stephens Consulting’s Neurocrine Biosciences NBIX Stock Holding History

Stephens Consulting’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6	Closed	-$755	–	890
2025 Q2	$755	Buy	+6	New	+$688	﹤0.01%	769

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Stephens Consulting's NBIX Position: Q3 2025 in Review

Stephens Consulting sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 6 shares — an estimated $755 sold.

Stephens Consulting first reported a position in NBIX in Q2 2025 and held it in 1 quarter. The position peaked at $755 in Q2 2025. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

Stephens Consulting reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
Stephens Consulting sold 6 Neurocrine Biosciences shares in Q3 2025, an estimated $755.
Stephens Consulting first reported a position in Neurocrine Biosciences in Q2 2025 and held it in 1 quarter.
Stephens Consulting's Neurocrine Biosciences position peaked at $755 in Q2 2025.
650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.